Navigation Links
Specially-bred mice help target an annual outbreak: the flu
Date:2/21/2012

PORTLAND, Ore As part of a national collaboration, Oregon Health & Science University researchers are studying specially bred mice that are more like humans than ever before when it comes to genetic variation. Through these mice, the researchers hope to better understand and treat an infectious disease that plagues us year in and year out: the flu.

The scientists aim to determine why some people suffer serious illness and even death when infected with influenza while others suffer only mild to moderate symptoms. The research is published in a special joint issue of the journals Genetics and G3: Genes, Genomes, Genetics, both publications of the Genetics Society of America.

The research was conducted within the Pacific Northwest Regional Center for Excellence (PNWRCE) for Biodefense and Emerging Infectious Diseases, a consortium of investigators with extensive expertise, and basic and translational research capacity directed at a broad range of pathogens. The cooperative effort has the goal of combating emerging or re-emerging infectious diseases that pose a serious threat to human health. The director of the PNWRCE is Jay Nelson, Ph.D., the founder and director of the Vaccine and Gene Therapy Institute at OHSU.

For decades, mice have played a key role in developing new treatments from the discovery of penicillin to the creation of polio vaccine. Because mice studied in labs are bred in a controlled manner, they are often genetically identical. Most of the time this is beneficial. The lack of genetic variation increases reproducibility and can help researchers more quickly determine a contributing factor to disease, but research on more complex diseases calls for mice to be more like humans who are genetically diverse. That's where this research project differs from many others.

The researchers are studying mice from the Collaborative Cross Program. Because these mice more closely reflect the genetic variation of humans, they may be the key to understanding some of today's most common, and most complex, diseases. In this case, the specially bred mice were used to study the varying immune response to the annual influenza outbreak.

In this research project, the scientists studied 44 groups of flu-infected mice that varied genetically. Due to this variation, the mouse reaction to influenza varied greatly, just as it does in the human population. The researchers then noted genetic differences that may have caused the variety of disease responses. Their ongoing work is to more clearly identify which genes cause these differences.

"Each year, annual influenza epidemics result in about 3 million to 5 million cases of severe illness," explained Shannon McWeeney, Ph.D., an associate professor of biostatistics and bioinformatics and head of the Division of Bioinformatics and Computational Biology at OHSU. "We see a broad spectrum of response to influenza infection ranging from patients with minor symptoms to the estimated 250,000 to 500,000 deaths worldwide."

"We want to understand what genetic factors influence this wide-ranging response. More importantly, with a better understanding of the genetic influence of disease response, we believe we can help in the development of better, safer vaccines that can target the most vulnerable population: the sick, elderly and young. We also want to determine if the genetic factors that impact flu response also play a role in the varying responses to other diseases. If so, this new research method could have a much broader impact," McWeeney said.


'/>"/>

Contact: Jim Newman
newmanj@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Energy network within cells may be new target for cancer therapy
2. Wayne State proves targeted tumor freezing therapy increases ovarian cancer survival
3. Salk researchers find new drug target for lung cancer
4. Researchers find important target playing role in tobacco-related lung cancers
5. Discovery predicts patient sensitivity to important drug target in deadly brain cancer
6. Drugs targeting chromosomal instability may fight a particular breast cancer subtype
7. A thought-provoking new therapeutic target for brain cancer?
8. FDA OKs Drug That Targets Rare Form of Cystic Fibrosis
9. New target for cancer therapy identified, preclinical study shows
10. Researchers Spot Potential Bile Duct Cancer Drug Targets
11. New therapeutic target to combat liver cancer discovered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... As health ... medicine known as “patient engagement.” The patient is doing more than filling out a ... , “There is an increasing emphasis in health care and research on the ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along ... updates for the primary prevention of cardiovascular diseases during the 15th Annual ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
Breaking Medicine Technology: